The company said it agreed under a merger agreement signed on October 20, 2026 to acquire all of the equity interests in American Oncology Network (AON) that it does not already own, and that it currently holds about 4% of AON.

1. 01

   The company said it agreed under a merger agreement signed on October 20, 2026 to acquire all of the equity interests in American Oncology Network (AON) that it does not already own, and that it currently holds about 4% of AON.

2. 02

   The company said the transaction values AON at an enterprise value of $2.4 billion, consisting of $2.3 billion at closing and contingent value rights (CVRs) of up to $100 million payable upon the satisfaction of certain conditions.

3. 03

   The company said that, assuming some AON stockholders take part in an equity rollover of up to 25% and retain 25% of AON, it expects to pay about $1.7 billion at closing to raise its ownership in AON to 75%.

4. 04

   The company said it expects full-year fiscal 2026 adjusted diluted EPS to be at least $17.90, which is at the high end of the previous range of $17.75 to $17.95.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.